Trials / Recruiting
RecruitingNCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 477 (estimated)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGM0504 | Administered SC |
| DRUG | BGM0504 | Administered SC |
| DRUG | Semaglutide | Administered SC |
Timeline
- Start date
- 2025-07-04
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2025-07-14
- Last updated
- 2025-10-28
Locations
4 sites across 1 country: Indonesia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07064486. Inclusion in this directory is not an endorsement.